Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Banner Week For Bayer In Japan

This article was originally published in PharmAsia News

Executive Summary

TOKYO - For the third time in a week Bayer released positive news related to Japan, saying Jan. 28 it had received marketing approval from the Ministry of Health, Labor and Welfare for Nexavar (sorafenib) for the treatment of advanced renal cell carcinoma. Four days earlier, the German company had said Nexavar received priority review from MHLW for the treatment of hepatocelluar carcinoma, a larger potential market
Advertisement

Related Content

Bayer Gains China’s Go-Ahead To Sell Liver Cancer Drug Nexavar In World’s Biggest Potential Market
Bayer Gains China’s Go-Ahead To Sell Liver Cancer Drug Nexavar In World’s Biggest Potential Market
Nexavar Survival Study In Asia-Pacific Patients With Liver Cancer Halted Early
Nexavar Survival Study In Asia-Pacific Patients With Liver Cancer Halted Early
Advertisement
UsernamePublicRestriction

Register

SC066767

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel